Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Feature|Articles|June 9, 2025
Fully Remote Telehealth Cancer Clinical Trial Aims to Expand Treatment Access Nationwide
Author(s)Tony Berberabe, MPH
Fact checked by: Sabrina Serani
A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient participation and care coordination nationwide.
Advertisement
Advertisement
A fully remote phase 2 telehealth trial (NCT06906562)1 that delivers oral pancreatic treatment directly to patients’ homes while coordinating care with local oncologists was launched recently at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute (OSUCCC-James). The trial, which opened May 8, 2025, seeks to enroll patients with FGFR-mutated pancreatic cancer.
Related to this article
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
The phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202) is exploring alisertib plus paclitaxel in small cell lung cancer after immunotherapy and chemotherapy.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement